« The Research Works Act: One (Two!) Against and One For |
Main
| Dapagliflozin Goes Down (For the Last Time?) »
January 19, 2012
Takeda Announces Cuts
Posted by Derek
2,800 over the next four years. More of them are in Europe than in the US (via the Nycomed acquisition), but there are hundreds of positions to be lost in this country, too. For now, the company seems to be just saying that they'll be in all parts of the organization, without much in the way of details. Those will, in time, become all too apparent.
Add that to last week's Novartis announcement (about 2,000 jobs, mostly in sales and marketing), and we're not off to a great 2012 on this front, are we?
Comments (15)
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- › Chemistry Software Questions Here
- › An Engineered Rhodium-Enzyme Catalyst
- › Chemistry Software Questions Answered Monday
- › More on That Crowdsourced CNS Research
- › Thanksgiving Synthesis
- › TauRx Goes Into Phase III For Alzheimer's
- › The Galaxy Is Full of Gunk
- › And Since We're Talking About Insider Trading
1. You're Pfizered on January 19, 2012 9:17 AM writes...
And the hits keep right on coming...
Bets on who is next to purge?
Permalink to Comment2. Chemjobber on January 19, 2012 9:39 AM writes...
I do not enjoy waiting for shoes to drop, but I fear there are more to come.
Permalink to Comment3. Just sayin' on January 19, 2012 9:59 AM writes...
And here I am reading C&EN's coverage of the recent JP Morgan Healthcare Conference in San Francisco. Gotta love the quotes from the movers and shakers:
"The tenor is definitely better this year."
"...rational optimism..."
"Good money available for good products."
"We are very bullish right now on the environment for early-stage life sciences."
Permalink to Comment4. Anonymous on January 19, 2012 10:03 AM writes...
At least one thing is for sure right now according to the news: Takeda is closing the whole R&D facility with round about 700 employees in Konstanz/Germany. This is the former Byk-Gulden and Altana site where draugs like pantoprazole or roflumilast (trade name Daxas) were discovered.
Permalink to Comment5. anonymous on January 19, 2012 10:07 AM writes...
At least one thing is for sure right now according to the news: Takeda is closing the whole R&D facility with round about 700 employees in Konstanz/Germany. This is the former Byk-Gulden and Altana site where draugs like pantoprazole or roflumilast (trade name Daxas) were discovered.
Permalink to Comment6. PharmaHeretic on January 19, 2012 11:25 AM writes...
Any guesses on the end game of pharma? The upper management can't pay themselves that much if they go all generic, because of lower profits.
Permalink to Comment7. Anonymous on January 19, 2012 1:22 PM writes...
Why did they buy the company in the first place? They obviously wanted something, and it wasn't the staff. Happens time and time again. How is this a sensible way to run a global economy?
Permalink to Comment8. @PharmaHeretic on January 19, 2012 3:58 PM writes...
Courtesy of Luke Timmerman at Xconomy, here is a frightening look into Chris Viehbacher's (CEO of Sanofi-Aventis) pharma strategery:
Q: On Sanofi’s outreach strategy with U.S. researchers, particularly in the Boston area following the Genzyme acquisition:
A: One of the main rationales for doing the Genzyme deal was to have a strong presence in research in the U.S., and clearly the first choice is Cambridge. Our vision for research is one of open collaboration. How companies do research is evolving, and certainly we are evolving. Traditionally, we’ve had big research centers, and we are trying to get a lot more balance between internal research and external research. Right now, it’s about a 70/30 ratio between internal to external. My objective is to bring that to about a 50/50 balance.
Permalink to Comment9. CR on January 19, 2012 4:29 PM writes...
Viehbacher wants "open collaboration"...wasn't that what Abby PharmTech was providing?
Permalink to Comment10. anonymous on January 19, 2012 8:34 PM writes...
@1. You're Pfizered:
Permalink to CommentBelieve me when I tell you (relative to your question) that you place a high wager on Merck (and the song plays on....)!
11. anonymous on January 19, 2012 8:34 PM writes...
@1. You're Pfizered:
Permalink to CommentBelieve me when I tell you (relative to your question) that you can place a high wager on Merck (and the song plays on....)!
12. Ginsberg on January 20, 2012 8:05 AM writes...
Alnylam is laying off 33% of their staff now. That amounts to about 56 jobs. Small potatoes compared to Tekeda but still a lot of money and man hours have been wasted on the RNAi snake oil.
Permalink to Comment13. LegaceMerckguy on January 20, 2012 6:37 PM writes...
@ 11 and 1: I bet it's Merck also. Every year for the last 10 we have had some sort of layoff. I can tell you one thing, I am waiting for our Abby Pharmtech. It really is only a matter of time.
Permalink to Comment14. PorkPieHat on January 21, 2012 7:55 PM writes...
While what Alnylam was doing was really fascinating, it never struck me as being commercially viable.
Permalink to Comment15. Chrispy on July 30, 2012 6:28 AM writes...
Novo Nordisk just shed 40 odd in the UK and several hundred in Europe. Anything to do with Greece not being able to pay for it's Insulin?????
Permalink to Comment